Opinion

Video

Colorectal Cancer: Updates from the GALAXY Arm in CIRCULATE-Japan

Author(s):

John L. Marshall, MDBenjamin Weinberg, MD

Focusing on the GALAXY arm in the CIRCULATE-Japan study, experts on colorectal cancer discuss how recent data are informing the evolving treatment landscape.

Related Videos
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Amin Nassar, MD
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Pashtoon Murtaza Kasi, MD, MS
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Related Content
Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Sarah ES Leary, MD, MS, of Fred Hutchinson
May 28th 2024

Tovorafenib Offers an Efficacious Option for R/R BRAF-Positive Pediatric Low-Grade Glioma

Matthew Lunning, DO, FACP, associate professor, Division of Oncology & Hematology, associate vice chair, research, Department of Internal Medicine, assistant vice chancellor, clinical research, University of Nebraska Medical Center; Sarah Rutherford, MD, assistant professor, medicine, Division of Hematology/Oncology, Weill Cornell Medicine
April 18th 2024

Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Allliance; associate professor, Department of Medicine, Division of Oncology, clinical director, Genitourinary Cancers Program, University of Washington School of Medicine; associate member, Clinical Research Division, Fred Hutchinson Cancer Center
May 23rd 2024

Advances With Erdafitinib Exemplify the Push For Precision Medicine in Urothelial Cancer

FDA
May 16th 2024

FDA to Hold End-of-Phase 2 Meeting for Botensilimab Plus Balstilimab in R/R mCRC